PTC CLINIC
Informace pro odborníky

Reference, klinické a dozimetrické studie karcinom ledvin

1. Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2. PMID: 38423047.
2. Tetar SU, Bohoudi O, Senan S, Palacios MA, Oei SS, Wel AMV, Slotman BJ, Moorselaar RJAV, Lagerwaard FJ, Bruynzeel AME. The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer. Cancers (Basel). 2020 Sep 25;12(10):2763. doi: 10.3390/cancers12102763. PMID: 32992844; PMCID: PMC7601380
3. Siva, Shankar & Chesson, Brent & Bressel, Mathias & Pryor, David & Higgs, Braden & Reynolds, Hayley & Hardcastle, Nicholas & Montgomery, Rebecca & Vanneste, Ben & Khoo, Vincent & Ruben, Jeremy & Lau, Eddie & Hofman, Michael & De Abreu Lourenco, Richard & Sridharan, Swetha & Brook, Nicholas & Martin, Jarad & Kron, Tomas & Foroudi, Farshad. (2018). TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney – FASTRACK II. BMC Cancer. 18. 10.1186/s12885-018-4916-2.